Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB859,58601,12
PKN75,8275,9-1,32
Msft-1,75
Nokia4,7024,747-2,15
IBM-0,88
Daimler AG7171,02-1,07
PFE-1,30
18.09.2021 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 17.09.2021
Sangamo Biosci (SGMO.O, NASDAQ Cons)
Závěr k 17.9.2021 Změna (%) Změna (USD) Objem obchodů (ks)
9,55 3,47 0,32 2 226 732
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 18.09.2021
Popis společnosti
Obecné informace
Název společnostiSangamo Therapeutics Inc
TickerSGMO
Kmenové akcie:Ordinary Shares
RICSGMO.O
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2020
Poslední známé čtvrtletní výsledky30.06.2021
Počet zaměstnanců k 31.12.2020 413
Akcie v oběhu k 02.08.2021 145 337 046
MěnaUSD
Kontaktní informace
Ulice7000 MARINA BLVD
MěstoBRISBANE
PSČ94005
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon15 109 706 000
Fax13026555049

Business Summary: Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.
Financial Summary: BRIEF: For the six months ended 30 June 2021, SangamoTherapeutics Inc revenues increased 56% to $54.2M. Net lossincreased 18% to $93.1M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Higher net loss reflects OtherResearch and development increase of 39% to $106.8M(expense), Stock Based Compensation in R&D increase of 51%to $9.7M (expense).
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Research and Development in Biotechnology
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research



  • Poslední aktualizace: 18.09.2021
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorAlexander Macrae5814.06.201601.06.2016
Chief Financial Officer, Senior Vice PresidentPrathyusha Duraibabu4201.06.202114.06.2019
Executive Vice President, Chief Business OfficerD. Mark McClung5801.05.202001.05.2020
Executive Vice President - Technical OperationsR. Andrew Ramelmeier5916.09.201916.09.2019
Senior Vice President, Chief Scientific OfficerJason Fontenot5101.01.202112.03.2019
Senior Vice President, Head of DevelopmentRobert Schott6301.02.202101.02.2021